Comparative Pharmacology
Head-to-head clinical analysis: LEVOCETIRIZINE DIHYDROCHLORIDE versus VISTARIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOCETIRIZINE DIHYDROCHLORIDE versus VISTARIL.
LEVOCETIRIZINE DIHYDROCHLORIDE vs VISTARIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levocetirizine is a selective antagonist of peripheral histamine H1 receptors, blocking histamine-induced allergic responses by inhibiting H1 receptor activation in the gastrointestinal tract, blood vessels, and respiratory tract.
Hydroxyzine is a piperazine derivative antihistamine that acts as a competitive antagonist of histamine H1 receptors, thereby suppressing histamine activity in the subcortical area of the central nervous system. It also has anxiolytic, sedative, antiemetic, and antispasmodic effects.
5 mg orally once daily in the evening.
Oral: 50-100 mg 4 times daily; IM: 25-100 mg every 4-6 hours as needed.
None Documented
None Documented
Terminal elimination half-life: 7-11 hours in adults. Clinically, this supports once-daily dosing; may be prolonged in renal impairment (creatinine clearance <30 mL/min).
Terminal elimination half-life: 20-25 hours in adults; prolonged in hepatic impairment or elderly; steady-state achieved in ~4-5 days.
Renal: 85% as unchanged drug (70%) and metabolites (15%); fecal: 13%; biliary: minimal (<2%).
Primarily hepatic metabolism; <1% excreted unchanged in urine; biliary/fecal elimination of metabolites accounts for approximately 50-60% of total clearance.
Category A/B
Category C
Antihistamine
Antihistamine